Patents Assigned to Kinetek Pharmaceuticals, Inc.
  • Patent number: 6548266
    Abstract: An assay system is provided for detecting the enzymatic activity of a phosphorylation enzyme. The enzyme may be a phosphatase or protein kinase. The substrate for the enzyme is immobilized on a solid support via covalent or non-covalent binding through a signal enhancing polymer. The immobilized substrate provides an enhanced signal to background ratio when compared to a substrate in solution. The methods are easily adapted to high throughput screening systems.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: April 15, 2003
    Assignee: Kinetek Pharmaceuticals, Inc.
    Inventors: Zaihui Zhang, Jasbinder Sanghera, Shisen Wang
  • Patent number: 6514972
    Abstract: A compound of the formula wherein, independently at each occurrence, v, w, and x are selected from C, N, O, and S, with H substitution as needed to fulfill open valence sites; y and z are selected from N and C, with H substitution as needed to fulfill open valence sites, with the proviso that each of w, v, x, y and z is not simultaneously C; the ring formed from v, w, x, y and z may be saturated or unsaturated; and R1, R2, R3 and R4 are selected from hydrogen, alkyl, aryl, alkaryl, aralkyl, heteroalkyl, and heteroaryl; wherein any adjacent two of R1, R2, R3 and R4 may join together to form a 5, 6 or 7-membered carbocyclic or heterocyclic ring, with the proviso that each of R1, R2, R3 and R4 is not simultaneously hydrogen. Pharmaceutical compositions of said compounds, and methods of use in the treatment of biological conditions including cellular hyperproliferation, are disclosed.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: February 4, 2003
    Assignee: Kinetek Pharmaceuticals, Inc.
    Inventors: Zaihui Zhang, Xinyao Du, Serguei Sviridov, Greg Chopiuk
  • Patent number: 6436915
    Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: August 20, 2002
    Assignee: Kinetek Pharmaceuticals, Inc.
    Inventors: Zaihui Zhang, Timothy Scott Daynard, Shisen Wang, Mikhail Chafeev
  • Patent number: 6420400
    Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: July 16, 2002
    Assignee: Kinetek Pharmaceuticals, Inc.
    Inventors: Zaihui Zhang, Jun Yan, Danny Leung, Shisen Wang, Penelope C. Costello, Jasbinder Sanghera
  • Patent number: 6344359
    Abstract: A rapid colorimetric assay is provided for determining the concentration of vanadyl and vanadate ion species, and total vanadium concentration, in a sample. A sample suspected of containing vanadium in one or more of these oxidation states is combined with a colorimetric substrate that will provide for different absorption spectra with vanadyl and vanadate complexes. Suitable colorimetric substrates include halogenated hydroxyquinolines, e.g. broxyquinoline (DBHQ). The solvent and assay conditions are chosen to minimize oxidation of the vanadium. The absorbance of the sample is then read at two wavelengths, one that indicates the presence of both vanadyl and vanadate, and one that indicates the presence only of one species, generally vanadate. By comparison to a standard curve, the total concentration and the species concentration of vanadium in the sample is determined.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: February 5, 2002
    Assignee: Kinetek Pharmaceuticals, Inc.
    Inventors: Jeffery Wheeler, Zaihui Zhang
  • Patent number: 6291447
    Abstract: Novel granulatimide compounds and pharmaceutical formulations thereof are provided.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: September 18, 2001
    Assignees: The University of British Columbia, Kinetek Pharmaceuticals, Inc.
    Inventors: Raymond Andersen, Michel Roberge, Jasbinder Sanghera, Daniel Leung, Edward Piers, Roberto GS Berlinck, Robert Britton
  • Patent number: 6214813
    Abstract: Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: April 10, 2001
    Assignee: Kinetek Pharmaceuticals, Inc.
    Inventors: Zaihui Zhang, Jun Yan, Danny Leung, Penelope C. Costello, Jasbinder Sanghera